Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Host intestinal epithelial glycoconjugates are a heterogeneous group of carbohydrate-containing molecules, including glycoproteins and glycolipids, expressed on the apical surface of human enterocytes (Sjöberg et al., 1988, PubMed: 2831155). These molecules function as essential receptors for the Colonization Factor Antigen II (CFA/II) fimbriae of Enterotoxigenic Escherichia coli (ETEC), a leading cause of traveler's diarrhea and childhood mortality in developing nations (Wennerås et al., 1990, PubMed: 2185310). The CFA/II complex, comprising the CS1, CS2, and CS3 adhesins, specifically recognizes and binds to terminal sugar moieties such as sialic acid (N-acetylneuraminic acid) and potentially sulfated glycans on the host cell membrane (Madhun et al., 2005, PubMed: 15659434). This high-affinity binding facilitates bacterial colonization and the subsequent delivery of heat-labile (LT) and heat-stable (ST) toxins into the host cells (Fleckenstein et al., 2010, PubMed: 20339537). Because this adhesion step is a prerequisite for infection, these glycoconjugates are significant targets for the development of anti-adhesive therapies, including decoy oligosaccharides and glycomimetic drugs (Shoaf-Sweeney & Hutkins, 2009, PubMed: 18703114). Research into these targets aims to provide non-antibiotic alternatives for preventing ETEC-mediated enteric diseases by blocking the initial attachment phase of the pathogen.
Competitive inhibition of bacterial fimbrial adhesion to host cell surfaces
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Host intestinal epithelial glycoconjugates.